Chlorproguanil hydrochloride-dapsone-artesunate

Revision as of 19:11, 27 September 2011 by WikiBot (talk | contribs) (Protected "Chlorproguanil hydrochloride-dapsone-artesunate": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine (Coartem®) and against chlorproguanil-dapsone Lapdap™. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]

References

  1. ↑ Das P (2006). "Promising anti-malarial enters phase II studies". Lancet Infect Dis. 6 (9): 551.

External links

Pills  This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://www.wikidoc.org/index.php?title=Chlorproguanil_hydrochloride-dapsone-artesunate&oldid=605314"